Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HTR1A | P08908 | 15/20 | 0.48 |
| ▸ | SLC6A4 | P31645 | 15/20 | 0.48 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.47 |
| ▸ | MEN1 | O00255 | 2/20 | 0.41 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.41 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.41 |
| ▸ | POLB | P06746 | 1/20 | 0.39 |
| ▸ | ATM | Q13315 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6615246 | 0.92 | HTR1A (0.51) | HTR1ASLC6A4CYP2D6MEN1KMT2A | |
| SCHEMBL6613554 | 0.91 | HTR1A (0.49) | HTR1ASLC6A4CYP2D6MEN1KMT2A | |
| SCHEMBL6617023 | 0.91 | HTR1A (0.59) | HTR1ASLC6A4MEN1KMT2APOLB | |
| SCHEMBL6616238 | 0.89 | HTR1A (0.49) | HTR1ASLC6A4CYP2D6MEN1KMT2A | |
| SCHEMBL6618111 | 0.89 | HTR1A (0.47) | HTR1ASLC6A4CYP2D6MEN1KMT2A | |
| SCHEMBL6411094 | 0.87 | HTR1A (0.49) | HTR1ASLC6A4CYP2D6MEN1KMT2A | |
| SCHEMBL6411606 | 0.87 | HTR1A (0.49) | HTR1ASLC6A4CYP2D6MEN1KMT2A | |
| SCHEMBL6618081 | 0.87 | HTR1A (0.46) | HTR1ASLC6A4CYP2D6 | |
| SCHEMBL6614584 | 0.86 | HTR1A (0.55) | HTR1ASLC6A4MEN1KMT2APOLB | |
| SCHEMBL6615932 | 0.85 | ALDH1A1 (0.44) | HTR1ASLC6A4MEN1KMT2AALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1466901-A1 | SEROTONINE REUPTAKE INHIBITOR | SUMITOMO PHARMACEUTICALS COMPANY, LIMITED (JP) | 2004-10-13 | — | — | EP | disclosed |